Asymchem Announces Opening of R&D site near Boston, Massachusetts
Asymchem Laboratories has opened a new research and development site in Woburn, Massachusetts, named Asymchem Boston, to enhance its global operations. This facility will focus on early-stage R&D services, including chemical process development and formulation studies for small molecules, peptides, and oligonucleotides. Currently operational with 6,000 sqft of lab space, expansion plans are set for 2023 to include a kilo-lab and additional support capabilities. Asymchem aims to better serve biotech clients and connect with manufacturing sites in China.
- Expansion into Woburn, Massachusetts, enhances global footprint.
- New facility focuses on early-stage R&D for pharmaceuticals.
- Immediate operational capacity of 6,000 sqft with plans for further expansion.
- None.
TEDA TIANJIN, P.R. China, Dec. 19, 2022 /PRNewswire/ -- Asymchem Laboratories (Tianjin) Co., Ltd. (stock code: 002821.SZ/6821.HK) ("Asymchem"), a leading CDMO serving the global pharmaceutical and biotech industry, announced today their opening of a new site in Woburn, Massachusetts – Asymchem Boston, a wholly owned subsidiary of Asymchem Group, as an important step to expand Asymchem's global footprint. The new Boston site is focused on providing early-stage R&D services including chemical process development, pre-formulation study and formulation development for small molecules, peptides, and oligonucleotides.
After establishing the location in August 2022, the site is now ready for full operation. Currently there is 6000 sqft of existing lab space that includes process and analytical labs, and space to expand in an additional 4500 sqft. Solid characterization and pre-formulation labs will be ready in Q1 2023. By Q3 2023 continued expansion will include a fully functional kilo-lab, formulation R&D, and oligonucleotide and peptide lab to support drug substance and drug product development and non-GMP production.
Asymchem Boston not only provides direct service to biotech clients, but also serves as a liaison between its China-based manufacture sites and the company's partners. Though the site's current focus is on small molecules, it will soon engage with more oligonucleotide and peptide work within the next year. From medicinal chemistry support to IND-enabling, the site will be equipped with the capacity to assist in early-stage process development for both drug substance and drug product.
"Asymchem has been working diligently in recent years to bring biotech clients an even more well-rounded CMC experience when managing early-stage projects. The company's expansion to Boston has become an integral part of this journey to better serve Asymchem's national and global partners." said, Dr. Hao Hong, Chief Executive Officer of Asymchem Group.
Founded in 1999, Asymchem (stock code: 002821.SZ/6821HKE) is a leading global integrated Contract Development and Manufacturing Organization (CDMO) providing innovative drug R&D and manufacturing. Asymchem is supported by 9500 employees based in PR China, US, and EU. Our mission is to be an essential player in the global pharmaceutical supply chain supporting drug development with innovative technological solutions in small molecule drug development and production.
View original content to download multimedia:https://www.prnewswire.com/news-releases/asymchem-announces-opening-of-rd-site-near-boston-massachusetts-301706389.html
SOURCE Asymchem
FAQ
What is Asymchem's new facility in Woburn, Massachusetts focused on?
When was the Woburn site established?
What services will Asymchem Boston provide?
What is the size of the lab space at the new Woburn facility?
What are the future expansion plans for Asymchem Boston?
